What are the available radionuclide thyroid scan modalities (I‑123 scintigraphy, I‑131 scintigraphy, technetium‑99m pertechnetate) and how is radioactive iodine (I‑131) therapy used in managing differentiated thyroid cancer?

Types of Thyroid Scans and Radioiodine Therapy in Thyroid Cancer

Radionuclide Thyroid Scan Modalities

Three primary radionuclide imaging modalities are available for thyroid evaluation: I-123 scintigraphy, I-131 scintigraphy, and Tc-99m pertechnetate scanning, each with distinct clinical applications in differentiated thyroid cancer management.

I-123 Scintigraphy

• Diagnostic imaging agent with lower radiation exposure compared to I-131
• Recommended dose: 3.7-14.8 MBq (100-400 µCi) orally 1
• Lower doses (100 µCi) for uptake studies alone; higher doses (400 µCi) for thyroid imaging
• Imaging typically initiated 6 hours post-administration 1
• Superior to Tc-99m for post-thyroidectomy remnant estimation 2
• Capsules usable up to 30 hours after calibration 1

I-131 Scintigraphy

• Dual diagnostic and therapeutic capability
• Post-therapy I-131 whole body scans reveal thyroid remnants more accurately than diagnostic scans 2
• Can be used diagnostically to determine if lesions are iodine-avid before committing to therapeutic doses 3
• Essential for detecting distant metastases and guiding treatment decisions

Tc-99m Pertechnetate

• FDA-approved for thyroid imaging in both adults and children 4
• Provides functional assessment of thyroid tissue uptake and distribution 5
• Nearly 100% positive predictive value for remnant detection when performed immediately before I-131 treatment 6
• Sensitivity of 77% (patient-based) and 59% (site-based) for unequivocally positive uptake 6
• Best predictor of successful ablation when scan is negative (P<0.001) 7
• Significantly inferior to diagnostic I-131 scan for post-thyroidectomy remnant estimation and should not replace it 2
• Useful as alternative screening tool in low-risk patients to predict ablation success 7

Critical distinction: While Tc-99m pertechnetate has excellent positive predictive value for immediate pre-treatment assessment, diagnostic I-131 scanning remains superior for comprehensive remnant evaluation 2. Ultrasound provides minimal information for remnant estimation 2.

---

Radioactive Iodine (I-131) Therapy Applications

High-Risk Patients

RAI therapy is systematically indicated for all high-risk patients using high-administered I-131 activity with thyroid hormone withdrawal preparation 3. High-risk features include:

• Distant metastases
• Gross extrathyroidal extension
• Incomplete tumor resection
• Aggressive histology

Distant Metastases Management

For patients with distant metastases, administer 100-200 mCi (3.7-7.4 GBq) of I-131 after TSH stimulation 8, 3.

Pulmonary Metastases

• Diffuse lung micro-metastases: Curative RAI therapy with multiple cycles every 6 months for 1-2 years until disappearance on post-therapy CT 3
• Macro-metastases (>1 cm): Iterative I-131 therapy at 100-200 mCi under thyroid hormone withdrawal for as long as uptake persists and clinical/biochemical response continues 3
• Approximately 40% of patients with iodine-avid metastases achieve complete remission with cumulative doses <600 mCi (22.2 GBq) 3
• Best outcomes: Early-detected, small, well-differentiated metastases with high RAI avidity 3

Bone Metastases

RAI therapy indicated as long as uptake persists on post-therapy scan with documented response, systematically accompanied by precise radiological evaluation and neurologic risk-pain-stability assessment 3. Local consolidation treatment or surgical resection may be necessary prior to I-131 therapy 3.

Locoregional Disease

Biochemical Evidence Without Structural Disease

Second I-131 treatment at 100 mCi recommended for diagnostic and therapeutic purposes, preferably after thyroid hormone withdrawal 3. Treatment may be repeated depending on tumor response.

Non-Resectable Locoregional Disease

At least one RAI treatment at 100 mCi empiric activity, preferably after thyroid hormone withdrawal 3. Repeat based on tumor response.

Persistent/Recurrent Disease After Surgery

Additional I-131 treatment at 100 mCi after targeted therapeutic approach (surgery, external radiotherapy), with treatment repeated based on response 3.

Patient Preparation

Thyroid hormone withdrawal is the strongly recommended preparation method for metastatic disease 3.

Critical caveat: If thyroid hormone withdrawal is contraindicated (medical/psychiatric comorbidities, hypopituitarism risk), off-label rhTSH may be used after validation by multidisciplinary team meeting 3. However, further studies are needed before implementing rhTSH as standard preparation for distant metastasis treatment 3.

TSH Suppression Strategy

• Maintain TSH <0.1 mIU/L between treatments for patients with persistent structural disease (unless contraindications exist) 8, 3
• After excellent response: TSH 0.5-2 mIU/L 8
• Intermediate-to-high risk with incomplete response: TSH 0.1-0.5 mIU/L 8

RAI-Refractory Disease Recognition

Non-RAI-avid lesions and those losing ability to concentrate RAI or progressing despite RAI avidity should be considered RAI-refractory 8. These patients require alternative systemic therapy:

• Lenvatinib and sorafenib are standard first-line systemic therapy for RAI-refractory DTC 8
• Lenvatinib preferred (ESMO-MCBS score: 3 vs. 2 for sorafenib) 8

Common Pitfalls to Avoid

1. Do not use Tc-99m or ultrasound as replacement for diagnostic I-131 scanning for remnant estimation 2
2. Do not continue RAI therapy indefinitely—recognize RAI-refractory disease early (lack of uptake, progression despite uptake) 8
3. Do not use rhTSH routinely for metastatic disease—reserve for patients who cannot tolerate hypothyroidism 3
4. Elderly patients with poorly differentiated carcinoma, large metastases, and high FDG avidity have poor RAI response—consider early transition to systemic therapy 3